secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2026-05-01T23:59:59+00:00
Accession:  0001193125-26-201397
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Biotherapeutics receives Nasdaq delisting notice for market value deficiency
--------------------------------------------------------------------------------

- Nasdaq notified Atara on April 30, 2026, that its MVLS fell below $50M for 30 consecutive business days.
- Company has 180 calendar days, until October 27, 2026, to regain compliance by closing at $50M+ for 10+ consecutive days.
- Stock continues trading on Nasdaq Global Select under ticker ATRA; company may consider transfer to Nasdaq Capital Market.
- If not compliant by deadline, Nasdaq will provide delisting notice; Atara may appeal to a Hearings Panel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526201397/0001193125-26-201397-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526201397/atra-20260430.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-201397

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer